Vermont
Requires Coverage of Comprehensive Biomarker Testing
No
Highlighted Disparity
No racial disparities were found in Vermont for these lung cancer metrics
Lung Cancer Rates
New Cases:
- The rate of new lung cancer cases in Vermont is 54.0 and not significantly different than the national rate of 52.8.
- It ranks 23rd among all states, placing it in the average tier.
- Over the last five years, the rate of new cases in Vermont did not change significantly.
- In 2022, the most recent year of data available for this report, the COVID-19 pandemic continued to disrupt access to medical care, including delays and reductions in cancer diagnoses and screening. This led to a decline in incidence rates for most cancers, including lung cancer, and should not be interpreted as a reduction in the underlying cancer burden.
5-Year Survival Rate:
- The percent of people alive five years after being diagnosed with lung cancer (the survival rate) in Vermont is 33.4%, which is significantly higher than the national rate of 29.7%.
- It ranks 7th among the 39 states with survival data, placing it in the above average tier.
- Over the last five years, the survival rate in Vermont improved by 29%.
Early Diagnosis:
- In Vermont, 34.5% of cases are caught at an early stage, which is significantly higher than the national rate of 28.1%.
- It ranks 3rd among the 50 states with data on diagnosis at an early stage, placing it in the top tier.
- Over the last five years, the early diagnosis rate in Vermont did not change significantly.
Lung Cancer Treatment
Biomarker Coverage:
- Vermont has yet to require any insurance coverage of comprehensive biomarker testing, including for lung cancer, as of August 2025.
Surgical Treatment:
- Vermont ranked 29th (out of the 49 states with available data) with 18.9% of cases undergoing surgery as part of the first course of treatment.
- This is significantly lower than the national rate of 20.7% and puts Vermont in the below average tier.
- Over the last five years, the percent of cases undergoing surgery in Vermont did not change significantly.
No Treatment:
- Vermont ranked 32nd (out of the 49 states with available data) with 21.2% of cases not receiving any treatment.
- This is not significantly different than the national rate of 21.0% and puts Vermont in the average tier.
- Over the last five years, the percent of cases receiving no treatment in Vermont did not change significantly.
Screening
Screening for High Risk:
- In Vermont, 23.8% of those at high risk were screened, which was not significantly different than the national rate of 18.2%.
- It ranks 7th among all states, placing it in the above average tier.
- Screening rates in this year’s report have been updated to correct an error in the data source and should not be compared to previous reports.
Prevention
Tobacco Use:
- The 2023 smoking rate in Vermont is 11.3% and not significantly different than the national rate of 11.4%.
- It ranks 20th among all states, placing it in the average tier.
Radon Exposure:
- In Vermont, 21.7% of radon test results were at or above the action level recommended by EPA.
- It ranks 24th among all states, placing it in the average tier.
Racial & Ethnic Disparities
Black individuals:
- Lung cancer rates are not available for Black individuals in Vermont due to too few cases over the time period to allow for accurate analysis.
Latino individuals:
- Lung cancer rates are not available for Latino individuals in Vermont due to too few cases over the time period to allow for accurate analysis.
Asian or Pacific Islander individuals:
- Lung cancer rates are not available for Asian or Pacific Islander individuals in Vermont due to too few cases over the time period to allow for accurate analysis.
Indigenous Peoples:
- Lung cancer rates are not available for Indigenous Peoples (American Indians/Alaska Natives) in Vermont due to too few cases over the time period to allow for accurate analysis.
Summary
Despite the early diagnosis rate in Vermont falling into the top tier, the state still has a lot of work to do to make sure that more of those at high risk for lung cancer are screened.
Vermont has yet to require any insurance coverage of comprehensive biomarker testing, which can help determine what treatment options would be best for individuals with lung cancer and other diseases.
Vermont falls into the average tier for percent of patients receiving no treatment. Some patients do refuse treatment, but issues such as fatalism and stigma can prevent eligible patients from accessing treatment that may save or extend their lives. All patients should work with their doctors to establish a treatment plan and goals.
Page last updated: October 29, 2025
